rhASB is an approved enzyme replacement therapy for patients with MPS VI.
Some clinicians wish to treat patients using reduced infusion times.
Feline MPS VI model was used to compare the pharmacodynamics and ADME of 2- v 4- hr IV infusions of rhASB.
No pharmacodynanmic differences were seen between 2- v 4-hour rhASB infusions given to MPS VI cats for 26 weeks.
Clinical studies of shorter rhASB infusion times are appropriate for MPS VI patients without infusion-associated reactions.